Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 371-376

  Tembhare, Prashant R ^a   Yuan, Constance M ^a   Venzon, David ^a   Braylan, Raul ^b   Korde, Neha ^a   Manasanch, Elisabet ^a   Zuchlinsky, Diamond ^a   Calvo, Katherine ^b   Kurlander, Roger ^b   Bhutani, Manisha ^a   Tageja, Nishant ^a   Maric, Irina ^b   Mulquin, Marcia ^a   Roschewski, Mark ^a   Kwok, Mary ^a   Liewehr, David ^a   Landgren, Ola ^a   Stetler Stevenson, Maryalice ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD81; Monoclonal gammopathy of uncertain significance; Multiple myeloma; Normal plasma cell immunophenotype; Smoldering multiple myeloma

Indexed keywords

CD81; MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE; MULTIPLE MYELOMA; NORMAL PLASMA CELL IMMUNOPHENOTYPE; SMOLDERING MULTIPLE MYELOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; ANTIGENS, CD56; ANTIGENS, CD81; BONE MARROW; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS;

EID: 84894273737     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.007     Document Type: Article

References (28)

1. Paiva B., Almeida J., Perez-Andres M., Mateo G., Lopez A., Rasillo A., et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010, 78:239-252.
2. Seegmiller A.C., Xu Y., McKenna R.W., Karandikar N.J. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol 2007, 127:176-181.
3. Yuan C.M., Stetler-Stevenson M. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. Semin Hematol 2011, 48:32-38.
4. Witzig T.E., Kimlinger T., Stenson M., et al. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998, 31:167-175.
5. Konoplev S., Medeiros L.J., Bueso-Ramos C.E., Jorgensen J.L., Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 2005, 124:414-420.
6. Mateo G., Montalban M.A., Vidriales M.B., Lahuerta J.J., Mateos M.V., Gutierrez N., et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008, 26:2737-2744.
7. Paiva B., Vidriales M.B., Perez J.J., Mateo G., Montalban M.A., Mateos M.V., et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009, 94:1599-1602.
8. Perez-Persona E., Vidriales M.B., Mateo G., Garcia-Sanz R., Mateos M.V., de Coca A.G., et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
9. Paiva B., Vidriales M.B., Mateo G., Perez J.J., Montalban M.A., Sureda A., et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009, 114:4369-4372.
10. Rawstron A.C., Child J.A., Tute R.M., Davies F.E., Gregory W.M., Bell S.E., et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council myeloma IX Study. J Clin Oncol 2013, 31:2540-2547.
11. Nowakowski G.S., Witzig T.E., Dingli D., Tracz M.J., Gertz M.A., Lacy M.Q., et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005, 106:2276-2279.
12. Dingli D., Nowakowski G.S., Dispenzieri A., Lacy M.Q., Hayman S.R., Rajkumar S.V., et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 2006, 107:3384-3388.
13. Paiva B., Vidriales M.B., Cervero J., Mateo G., Perez J.J., Montalban M.A., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
14. Liu H., Yuan C., Heinerich J., Braylan R., Chang M., Wingard J., et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma 2008, 49:306-314.
15. Ocqueteau M., Orfao A., Almeida J., et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998, 152:1655-1665.
16. Almeida J., Orfao A., Ocqueteau M., et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Brit J Haematol 1999, 107:121-131.
17. Lin P., Owens R., Tricot G., Wilson C.S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004, 121:482-488.
18. Tohami T., Drucker L., Shapiro H., Radnay J., Lishner M. Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 2007, 21:691-699.
19. Paiva B., Gutierrez N.C., Chen X., Vidriales M.B., Montalban M.A., Rosinol L., et al. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 2012, 26:1862-1869.
20. Kyle R.A., Durie B.G., Rajkumar S.V., Landgren O., Blade J., Merlini G., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
21. Jasper G.A., Arun I., Venzon D., Kreitman R.J., Wayne A.S., Yuan C.M., et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom 2011, 80(2):83-90.
22. Perez-Persona E., Mateo G., Garcia-Sanz R., Mateos M.V., de Las Heras N., de Coca A.G., et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Brit J Haematol 2010, 148:110-114.
23. Rawstron A.C., Owen R.G., Davies F.E., Johnson R.J., Jones R.A., Richards S.J., et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Brit J Haematol 1997, 97:46-55.
24. Rawstron A.C., Orfao A., Beksac M., Bezdickova L., Brooimans R.A., Bumbea H., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438.
25. Cannizzo E., Bellio E., Sohani A.R., Hasserjian R.P., Ferry J.A., Dorn M.E., et al. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom 2010, 78:231-238.
26. Peceliunas V., Janiulioniene A., Matuzeviciene R., Griskevicius L. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom 2011, 80:318-323.
27. Hermiston M.L., Xu Z., Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003, 21:107-137.
28. Jensen G.S., Mant M.J., Belch A.J., Berenson J.R., Ruether B.A., Pilarski L.M. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991, 78:711-719.